Background The use of antithrombotic agents, including anticoagulants, antiplatelet agents,
and thrombolytics has increased over the last decade and is expected to continue to rise …

The known and unknown risks of blood transfusion are incorporated within efforts to
establish patient blood management as a means to promote the availability and use of …

The COVID-19 pandemic has major implications for blood transfusion. There are uncertain
patterns of demand, and transfusion institutions need to plan for reductions in donations and …

Background: The AABB (formerly, the American Association of Blood Banks) developed this
guideline on appropriate use of platelet transfusion in adult patients. Methods: These …

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment
of non-hematologic malignancies. Many patient-related variables (eg, age, tumor type …

Purpose To provide evidence-based guidance on the use of platelet transfusion in people
with cancer. This guideline updates and replaces the previous ASCO platelet transfusion …

Background The effectiveness of platelet transfusions to prevent bleeding in patients with
hematologic cancers remains unclear. This trial assessed whether a policy of not giving …

Antibody–drug conjugates (ADCs) represent a novel and evolving class of antineoplastic
agents, constituted by monoclonal antibody linked to biologically active drugs, delivering …

This article provides guidance on the management of anticoagulation in patients with cancer-
associated thrombosis (CAT) and thrombocytopenia (defined here as a platelet count of< …

Background A substantial proportion of critically ill COVID-19 patients develop
thromboembolic complications, but it is unclear whether higher doses of thromboprophylaxis …